A global registry of women affected by COVID-19 in pregnancy and their babies, to guide treatment and prevention

ISRCTN ISRCTN68026880
DOI https://doi.org/10.1186/ISRCTN68026880
IRAS number 282655
Secondary identifying numbers 20QC5917, IRAS 282655
Submission date
29/04/2020
Registration date
30/04/2020
Last edited
28/08/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
COVID-19 is a condition caused by the coronavirus (called SARS-CoV-2) that was first identified in late 2019. This virus can infect the respiratory (breathing) system. Some people do not have symptoms but can carry the virus and pass it on to others. People who have developed the condition may develop a fever and/or a continuous cough among other symptoms. This can develop into pneumonia. Pneumonia is a chest infection where the small air pockets of the lungs, called alveoli, fill with liquid and make it more difficult to breathe.
In 2020, the virus has spread to many countries around the world and neither a vaccine against the virus or specific treatment for COVID-19 has yet been developed. As of April 2020, it is advised that people minimize travel and social contact, and regularly wash their hands to reduce the spread of the virus.
Groups who are at a higher risk from infection with the virus, and therefore of developing COVID-19, include people aged over 70 years, people who have long-term health conditions (such as asthma or diabetes), people who have a weakened immune system and people who are pregnant. People in these groups, and people who might come into contact with them, can reduce this risk by following the up-to-date advice to reduce the spread of the virus.
There is a need to rapidly collect and pool data on pregnant women affected by suspected or confirmed COVID-19 to inform treatment and preventative strategies in this and future outbreaks. The aim of this study is to create a global registry gathering data on the effect of SARS-CoV-2 infection in pregnancy from healthcare systems around the world. The researchers are endorsed by the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) and the International Federation of Gynecology and Obstetrics (FIGO) who will support the study through their members and networks.

Who can participate?
Women aged 18-50 who are pregnant and their babies, with suspected or confirmed COVID-19

What does the study involve?
Data will be collected between January 2020 and March 2021 focusing on miscarriage, fetal growth restriction and stillbirth, pre-term delivery and potential transmission to the baby. The study will also collect data on ultrasound diagnosis and neonatal care not included in other more general studies. Data entry can be performed by any healthcare professional in maternity services. The researchers will engage with obstetricians (Attendings/Consultants and those in training) and midwives to ensure data collection is as wide and full as possible. Investigators can register their interest to add data to the registry through the web page (https://pan-covid.org). Once registered they will be asked to provide confirmation of their local approval, which will allow data entry.

What are the possible benefits and risks of participating?
There are no direct benefits or risks of participation, the data gathered will be used to inform treatment and prevention of COVID-19.

Where is the study run from?
Imperial College Healthcare NHS Trust (UK)

When is the study starting and how long is it expected to run for?
January 2020 to September 2021

Who is funding the study?
UK Research and Innovation

Who is the main contact?
Dr Edward Mullins
edward.mullins@imperial.ac.uk

Study website

Contact information

Dr Edward Mullins
Public

Principal Investigator
Queen Charlotte's & Chelsea Hospital
Du Cane Road
London
London
W12 0HS
United Kingdom

ORCiD logoORCID ID 0000-0003-1886-6358
Phone +44 (0)20 3313 1111
Email edward.mullins@imperial.ac.uk

Study information

Study designObservational pregnancy register
Primary study designObservational
Secondary study designEpidemiological study
Study setting(s)Hospital
Study typePrevention
Participant information sheet https://pan-covid.org/Information-for-Participants.php
Scientific titlePregnancy and Neonatal Outcomes in COVID-19: a global registry of women with suspected COVID-19 or confirmed SARS-CoV-2 infection in pregnancy and their neonates; understanding natural history to guide treatment and prevention
Study acronymPAN-COVID
Study hypothesisTo understand the natural history of COVID-19 in pregnancy, in order to guide treatment and prevention during the outbreak.
Ethics approval(s)Approved 09/04/2020, North West - Haydock Research Ethics Committee (3rd Floor - Barlow House, 4 Minshull Street, Manchester, M1 3DZ, UK; +44 (0)2071048387 or +44 (0)2071048165; haydock.rec@hra.nhs.uk), ref: 20/NW/0212
ConditionCOVID-19 (SARS-CoV-2 infection) in pregnancy and neonates
InterventionThe study will form a global disease registry linked with other national data sources for women with suspected COVID-19 or confirmed SARS-CoV-2 in pregnancy and their neonates. Investigators can register their interest to add data to the registry through the web page (https://pan-covid.org). Once registered they will be asked to provide confirmation of their local approval, which will allow data entry. Data will be collected from 01/01/2020 to 31/03/2021 on miscarriage, pre-term delivery, fetal growth restriction and neonatal outcomes, to assess the effect of a SARS-CoV-2 infection.
Intervention typeOther
Primary outcome measure1. Confirmed SARS-CoV-2 infection in women in pregnancy or their neonates, measured using routine clinical data from 01/01/2020 to 31/03/2021
2. Suspected SARS-CoV-2 (defined as woman self-isolating for suspected COVID-19 with symptoms, symptoms will be recorded) measured using routine clinical data from 01/01/2020 to 31/03/2021
Secondary outcome measures1. Incidence of miscarriage measured using routine clinical data from 01/01/2020 to 31/3/2021
2. Incidence of fetal growth restriction and stillbirth measured using routine clinical data from 01/01/2020 to 31/3/2021
3. Incidence of preterm birth measured using routine clinical data from 01/01/2020 to 31/3/2021
4. Incidence of vertical transmission to the neonate measured using routine clinical data from 01/01/2020 to 31/3/2021
5. Co-morbidities measured using routine clinical data from 01/01/2020 to 31/3/2021
6. Medical history measured using routine clinical data from 01/01/2020 to 31/3/2021
7. Details of the delivery of baby/babies measured using routine clinical data from 01/01/2020 to 31/3/2021
Overall study start date01/01/2020
Overall study end date30/09/2021

Eligibility

Participant type(s)Patient
Age groupMixed
Lower age limit18 Years
Upper age limit50 Years
SexBoth
Target number of participantsApprox. 1000
Total final enrolment8239
Participant inclusion criteria1. Women aged 18-50 who are pregnant and their babies
2. Suspected COVID-19 or confirmed SARs-CoV-2 infection
3. Delivery or pregnancy loss between January 2020 and March 2021
Participant exclusion criteriaIndividuals who do not meet the inclusion criteria
Recruitment start date01/01/2020
Recruitment end date31/03/2021

Locations

Countries of recruitment

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Bosnia and Herzegovina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Ecuador
  • Egypt
  • England
  • Estonia
  • Germany
  • Greece
  • Guatemala
  • Hungary
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Latvia
  • Lebanon
  • Malta
  • Mexico
  • Netherlands
  • Nigeria
  • Peru
  • Portugal
  • Qatar
  • Romania
  • Russian Federation
  • South Africa
  • Spain
  • Thailand
  • Tunisia
  • Uganda
  • United Arab Emirates
  • United Kingdom
  • United States of America

Study participating centre

Imperial College Healthcare NHS Trust
Du Cane Road
London
W12 0HS
United Kingdom

Sponsor information

Imperial College London
University/education

South Kensington
London
SW7 2BU
England
United Kingdom

Phone +44 (0)20 7589 5111
Email y.borisova@imperial.ac.uk
Website http://www3.imperial.ac.uk/
ROR logo "ROR" https://ror.org/041kmwe10

Funders

Funder type

Research organisation

UK Research and Innovation
Government organisation / National government
Alternative name(s)
UKRI
Location
United Kingdom

Results and Publications

Intention to publish date31/10/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planThe weekly reports of case data will be made available on the study website. In addition, results will be submitted to scientific journals, available as open-access, in Autumn 2021.
IPD sharing planCTR, Cardiff University is responsible for building, maintaining, cleaning and analysing the database. All enquiries should be directed to the PI, Edward Mullins (Edward.mullins@imperial.ac.uk) or Julia Townson (townson@cardiff.ac.uk). The data will be available upon request and an agreed/signed data-sharing agreement. De-identified participant data will be made available to the scientific community with as few restrictions as feasible, whilst retaining exclusive use until the publication of major outputs. Cardiff University holds data for 15 years.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article protocol 29/01/2021 01/02/2021 Yes No
HRA research summary 28/06/2023 No No
Results article 19/07/2022 28/08/2024 Yes No

Editorial Notes

28/08/2024: Publication reference and total final enrolment added.
01/02/2021: Publication reference added.
30/04/2020: Trial's existence confirmed by the NIHR.